Podcasts about Eli Lilly

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die abgewendete Shutdown-Gefahr und die Gewinner und Verlierer der neuen Zinswelt. Außerdem geht es um Ginkgo Bioworks, Bayer, Alphabet, Merck, Pfizer, Novo Nordisk, Eli Lilly, Moderna, AT&T, Verizon, Comcast, T-Mobile, CVS Health, Warner Bros Discovery, Norwegian, Carnival, Black & Decker, AirBnB, Activision Blizzard, Service Now, Palo Alto, Arista Networks, Fortinet, Monster Beverages, Zoom, Apple, Alphabet, Cisco, Tesla, Booking, Meta, Nvidia, Costco, Paychex, Cadence, Fraport, Covestro, Pro7Sat.1, Lanxess, Encavis, Fresenius, Evonik, Siemens Healthineers, Fresenius Medical, Symrise, Ströer und Deutsche Telekom. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

A combination of public and private investments in neuroscience, government grants, and charitable donations are helping accelerate a wave of advancements and opportunities in the field of neuroscience. Recent clinical trial success for the second significant, disease-modifying drug to treat Alzheimer's is a critical milestone and a positive sign for the future of neuroscience. So, what does this mean for the healthcare investment landscape?Jeff Spiegel, US Head of BlackRock Megatrend, International and Sector ETFs across index and active strategies talks about these latest breakthroughs in neuroscience and why it demands a closer look when considering healthcare opportunities in your portfolio.Sources:United States Census Bureau, “Older People Projected to Outnumber Children for First Time in U.S. History,” March 13, 2018; United Nations, “2022 Revision of World Population Prospects,” 2022; Eli Lilly, “Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease,” May 3, 2023; FactSet, Springer Adis Insight, 2022; BlackRock analysis; Alzheimer's Association, ”2023 Alzheimer's disease facts and figures,” April 19, 2023; Data Bridge Market Research, “Global Traumatic Brain Injuries Treatment Market – Industry Trends and Forecast to 2029,” February 2022; Kuehn, Bridget M. "WHO: Pandemic Sparked a Push for Global Mental Health Transformation." JAMA 328.1 (2022): 5-7; Biogen, “FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder,” August 4, 2023; PLOS One, “Adversarial confound regression and uncertainty measurements to classify heterogeneous clinical MRI in Mass General Brigham,” March 2, 2023; U.S. Food and Drug Administration, “New Drug Therapy Approvals 2022,” January 2023.This content is for informational purposes only and is not an offer or a solicitation. Reliance upon information in this material is at the sole discretion of the listener.In the UK and Non-European Economic Area countries, this authorised and regulated by the Financial Conduct Authority. In the European Economic Area, this is authorised and regulated by the Netherlands Authority for the Financial Markets.For full disclosures go to Blackrock.com/corporate/compliance/bid-disclosuresSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode, I was joined by Sara Waxberg MacNew, Chief Scientific Officer at Design Sciences. On this episode Sara and I discuss: New FDA Guidance: Critical Task Definition for Combination Products Pre-Clinical HF Studies in readiness for IND Submission URRA Human Factors Validation vs. Design Validation Sara Waxberg McNew is the Chief Scientific Officer at Design Science, a human factors firm that specializes in healthcare. Sara has held roles previously in user centered design leadership at Eli Lilly, Philips Healthcare, and Baxter Healthcare. She is an active member of AAMI where she has contributed to the development and revision of human factors technical information reports and international standards. Learn more about Design Science's impact on Healthcare Technology by following @designscience on all social media platforms.

In this podcast episode, Anita Afzali, MD, MPH, MHCM, FACG, AGAF, and Aja McCutchen, MD, discuss how women in gastroenterology (GI) can embrace and enhance their value. These inspiring GI medicine experts propose a practical formula that involves ongoing, careful self-reflection and asking yourself how your strengths, core values, and interests can be aligned with professional endeavors. In addition, self-advocacy and self-allyship can serve as harmonious tools to drive action and positive change.   Presenters:Dr Anita Afzali is a Professor of Clinical Medicine, Interim Division Director of the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine, and the Associate Chief Medical Officer of the UC Health system in Cincinnati, Ohio. She is also a Co-Founder of Scrubs & Heels.Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant: AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Lilly, Pfizer, Takeda; provider of non-CME/CE services: AbbVie, Janssen, Pfizer, Takeda.Dr Aja McCutchen is a Partner and Physician Executive at Atlanta Gastroenterology Associates, a division of United Digestive in Atlanta, Georgia, and served as Co-Chair at the Scrubs & Heels 2023 Leadership Summit. Aja McCutchen, MD: consultant/advisor/speaker: Eli Lilly, Modify Health, Redhill Biopharm, Sanofi Regeneron, Takeda.Episode outline: Understanding and establishing your own market value; bringing that to your own organizationConsequences of being ill-equipped to pursue professional growth and developmentAdvocating for the value you bring to the professionNegotiation as a form of self-allyshipNegotiation categories to help support career success and protect work–life balanceOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 1: Finding Your Friendtors: Mentors, Sponsors, and AlliesPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GITo receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.

The yield on 10-year treasurys crossed the 4.5% mark for the first time since October 2007, but it's the benchmark's relationship with the 2 year that caught the attention of one of our traders. Why the steeply steepening yield curve could be setting up equities for a problem period. Plus manufacturing giant Jacobs Solutions counts Eli Lilly and Novo Nordisk as two of its biggest customers. How the company is benefiting from the surging demand for weight-loss drugs. Fast Money Disclaimer

Today's guest is Ramesh Durvasula, Senior Vice President of R&D IT at Eli Lilly. Ramesh joins Emerj Senior Editor Matthew DeMello on the program today to survey the biggest challenges in biotech research and how emerging capabilities, particularly in generative AI, are paving the way for a new future for the industry. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

1.The CPI numbers were released today. The August consumer price index rose 0.6% for the month, and was up 3.7% from a year ago. This number was expected so it was not a big surprise to the markets. Core CPI, which excludes volatile food and energy, increased 0.3% and 4.3% respectively, against estimates for 0.2% and 4.3%. The bottom line, the market expects the Fed to keep rates unchanged at the next meeting which is on September 20th. 2. Tomorrow we get the PPI number at 8:30am EST. 3. The ultimate pair trade, Buy Eli Lilly and sell McDonald's. 4. Today, all of the big tech CEOs are meeting in Washington DC. CEO's such as Elon Musk, Mark Zuckerburg, Sundai Pachai and many others are going to talk to the senators about AI. I'm not sure what is going to come out of this. 5. Gold is flat today, but it did pull down a little yesterday. As you know, gold often dips during options expiration so we should not rule that out. There is still some daily chart support around the $1913 level. 6. Bitcoin is trading up today by 0.25%. Bitcoin had a good pop yesterday, but I'm not sure it is anything more than some options expiration game playing this week. Visit Nick at: https://IntheMoneyStocks.comVisit Kerry at: https://FinancialSurvivalNetwork.comThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4295686/advertisement

Morgan Stanley boosted its Tesla share-price target by 60% to $400. Plus, Eli Lilly shares reach a new record high. J.R. Whalen reports.  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering: How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseases Having the DNA of an entrepreneur but taking the time to gain a big pharma foundation The harsh realities and characteristics required to start, fund, and grow a clinical-stage biotechnology company The need as a biotech CEO to be bullish, have confidence in your partners and be passionate about your disease... while celebrating the little successes Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel. He merged the company with Coya Therapeutics in 2021, where he currently serves as Chairman and CEO He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Apples China Problem, Immobilienverkäufe bei Vonovia und Hafenfantasie bei HHLA. Außerdem geht es um Unicredit, Commerzbank, Hamburger Hafen, Deutsche Bank, C3.ai, UiPath, Gamestop, Apple, AMC Entertainment, Novo Nordisk, Eli Lilly, Amgen, Viking Therapeutics, West Pharma, Becton Dickinson, Lonza, Biontech, Gerresheimer, Stevanato, West Pharma, VanEck US Fallen Angel High Yield Bond ETF (WKN: A3EEYM), Vodafone, Rolls Royce, der Telecom Italia, Las Vegas Sands, Ford Motor, Under Armor, Seagate, Transocean, Macys und Delta Airlines. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über den neuen wertvollsten Börsenkonzern Europas, eine peinliche Panne bei United Airlines und den Ritterschlag für eine Jahrhundertaktie. Außerdem geht es um Novo Nordisk, LVMH, United Airlines, Zscaler, AirBnB, ARM Holdings, Digital World Acquisitions, Tesla, United Internet, Krones, Energiekontor, Eckert & Ziegler, Thyssenkrupp Nucera, Ionos, Basler, Daiichi Sankyo, AstraZeneca, Roche, Chugai Pharmaceutical, Merck&Co, Bayer, Eli Lilly, Karuna, Zai Lab, Moderna, Viking Therapeutics, Madrigal Pharmaceuticals, ishares US Pharmaceuticals ETF (A0MMQW), SPDR S&P Biotech (WKN: A0MYHE), Principal Healthcare Innovators ETF (WKN: A2PFHA), L&G Pharma Breakthrough UCITS (WKN: A2H9XR). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this ACT ToxChats© episode, Dr. Meredith Steeves and Mr. Terry Leyden share their perspectives on the current hiring landscape for toxicologist roles in industry, how to find the right fit, tips for transitioning from a bench-based position, and how to prepare for and successfully navigate the interview and negotiation process. Dr. Steeves and Mr. Leyden have complementary roles in the hiring process for toxicologists in the biopharmaceutical industry. Dr. Steeves is a Senior Director of Toxicology and hiring manager at Eli Lilly and Mr. Leyden is a Certified Personnel Consultant and President of The Leyden Group, a Colorado-based professional recruiting and search firm. This podcast is of interest for toxicologists at all career stages, with a specific focus on trainees and early career professionals and is presented by the ACT Early Career Professional Subcommittee.

Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins.In this episode we talk with three experts about how this animal's unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Pamela Bush, Chief Business Officer at Predictive Oncology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pam, covering: The key aspects to successful deal-making learned over a decade with Eli Lily How a passion for curing cancer led Pamela to an opportunity to directly impact thousands of promising candidates How active machine learning is being used to screen molecules, help companies fail fast and increase the success of a molecule in clinical trials The challenge of selling a disruptive, game-changing platform that could become a vital decision tool in the future Pamela Bush, Ph.D. has over twenty years of experience in venture creation, finance, and business development in the life sciences industry. Pamela is the Chief Business Officer for Predictive Oncology where she leads the strategy and business development activities across the portfolio. Prior to joining Predictive Oncology, Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 100+ life sciences start-ups. Pamela holds a Ph.D. in Molecular Genetics and an MBA from Carnegie Mellon University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Stephen Reynolds, a partner at the law firm of McDermott, Will, and Emery, joins the Nexus Podcast to discuss some of the concerns and questions CISOs and other security executives may have about their personal liability and exposure during breach investigations. The short of it: Don't panic, but don't be unprepared either. In this case, preparation equates to having personal legal counsel available, and document everything during an incident.Reynolds and Eli Lilly associate VP and assistant general counsel Nick Merker presented on this topic at Black Hat under the context of the case and conviction of former Uber CISO Joe Sullivan. Sullivan was convicted of obstruction of justice and misprision of a felony for his role in covering up a breach at Uber. Reynolds cautions that CISOs always remember that corporate counsel represent the company, and any attorney-client privilege is to the company and not the individual. He also reminds leaders to document the facts and information available at the time key decisions were made during an incident.

Concern, uncertainty, excitement and optimism…words that could be used to sum up the State of Indiana's LEAP Innovation District, and its first tenant – Eli Lilly. Todd Dando and Jeff Wagner from Fluor Corporation join us for Episode 130 of the #LovinLebanon Podcast. Fluor Corporation is constructing the Lilly Campus, and Jeff and Todd provide progress updates…and answer some of your questions as well.  The pair also shares details on a chance for local businesses to collaborate with the project. Click the link to learn more about this opportunity:  http://events.r20.constantcontact.com/register/event?oeidk=a07ejxfrbsq077c3a41&llr=w9zl5xfbb  

What we do each day and how we define ourselves to others is critical to our identify and sense of self worth.  In this interview, we will explore the importance of identity as a foundational component of mental health recovery.  For those who are involved in designing social enterprise businesses, or creating more pathways to employment for people living with a mental illness in their community, this interview will provide ideas and inspiration.Paul Barry has had a distinguished career in this space, beginning as a teacher in a maximum security prison for Teach for America, and ending as the head of employment programs at the Village in Long Beach, a highly regarded mental health community under the direction of Mental Health America.  He holds a Masters in Education (Urban Specialty) from the University of Hartford and post-graduate certification in Managed Care from the CA School of Professional Psychology. Over his career, he developed the first community-based business of its kind that employed adults with developmental disabilities in Pasadena, CA in the early 80's (the “Hot Dog Building Company”).  He created, developed and managed a non-profit agency-owned competitive business, Corporate Cookie, in the Mid-Wilshire business district in Los Angeles in the late 80's.He moved on to become the Director of Employment and Community Integration at The Village in Long Beach. In this role, he started three agency-owned businesses (Deli 456, Village Maintenance Business & The Village Cookie Shoppe) and oversaw five job developers to identify community employment opportunities. As his career at The Village progressed, he moved from that role to Associate Director and ultimately Executive Director.The Village employment program was also awarded 1988 Program of the Year from the California State Dept of Rehabilitation.  In 1999 he received  Eli Lilly's National 1st place award for Social Worker of the Year.   And, in 2014, he accepted the award on behalf of the Village for the most innovative mental health program in the country, awarded by the National Council on Behavioral Health in Washington DC.  Articles and reports referenced in this interview.Corporate Cookie Wilshire Blvd 1990Corporate Cookie on Santa Monica Blvd 1995DMH E-News 9/29/16Accoglienza blog on The Importance of Work to Our Identity 2019Revisiting the Developed Versus Developing Country Distinction in Course and Outcome in Schizophrenia:  Results from ISoS, the WHO Collaborative Followup Project.  By Kim Hopper and Joseph Wonderling (2000)Podcast interview (2022) referenced in conversation between Dr. Mark Ragins and Dr. Dave Pilon discussing the 1990's Village Pilot

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Mike Martin, Chief Executive Officer at CAI. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering: How a passion for engineering led to a lifetime in life sciences - including 32 years with Eli Lilly Why working in China, Puerto Rico, and Ireland and the exposure to new cultures changed this ‘mid-west farm boy's view of the world A very short attempt at retirement... and what tempted Mike back into the working world Lessons learned from years of being the client, but also knowing when to dial down the client voice as a service provider As the CEO of CAI, Mike Martin guides a team of 800+ across the US, Europe, and APAC for the global professional services firm focused on engineering and quality consulting. With over 30 years in the pharmaceutical industry, including decades at Eli Lilly, Mike has experience in engineering, operational leadership, engineering leadership, and large-scale project management in diverse global settings, specifically major capital projects in the US, Puerto Rico, China, and Ireland. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

How does a school guidance counselor go on to generating over $3 billion dollars of sales in the pharmaceutical drug industry? Meet Alec Burlakoff who was the VP of sales at Insys Pharmaceuticals. You may have seen him on 60 minutes, maybe you have read his book "Selling Hard Lessons Learned." Netflix has a movie coming out about in October titled "Pain Hustlers." In the end the founder and 6 company executives were convicted. It was one of the first of its kind taking down executives with prison sentences in the pharmaceutical C-Suite. This is a fascinating story of a man that was told by his Dad he wanted Alec to avoid sales, so Alec got a masters in child psychology and became a guidance counselor and coach at a prestigious private school. One of the parents told Alec that he could get him an interview at Eli Lilly. Alec wanted to make more money and went to the interview and became the Rookie of the Year at Eli Lilly. He made a name for himself then jumped to Johnson and Johnson before he landed at InSys. Alec is a man who is straight forward and honest about what he did and how he did it. He also gives us a behind the scenes look of doing your prison time during COVID. This is an incredible rollercoaster story. You won't want to miss this one.

There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.See omnystudio.com/listener for privacy information.

There's a tectonic shift happening in obesity research and drug development, BioCentury Editor in Chief Simone Fishburn said on the latest BioCentury This Week podcast. Fishburn and colleagues discuss how the success of obesity therapies from Novo Nordisk and Eli Lilly targeting the incretin axis has galvanized a wave of drug development with different molecular targets as well as last week's threshold-setting cardiovascular outcomes trial data from Novo and recent obesity deals by the two companies.BioCentury's editors also discuss takeaways from Fishburn's conversation with Flagship Pioneering's Noubar Afeyan on The BioCentury Show, plus the Scleroderma Research Foundation's plans to bring the platform trial model to scleroderma.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen KI-Liebling als Spielverderber, Crash bei Roblox und wenig Magie bei Disney. Außerdem geht es um Super Micro Computer, Nvidia, Marvell, Baidu, ByteDance, Tencent, Alibaba, Palanti, C3.AI, Upstart, Unicredit, WeWork, SanPaolo, Delivery Hero, Novo Nordisk, Maersk, DSV, Vestas, Coloplast, Genmab, Hansen Holding, Orsted, Eli Lilly, LVMH, Uber, MSCI Denmark (WKN: A1W8E4), Xtrackers MSCI Nordic UCITS ETF (WKN: A1T791), ARK Innovation (WKN: ARKK), Nikko AM ARK Disruptive Innovation (WKN: LU1861558580), HANetf HAN-GINS Tech Megatrend Equal Weight (WKN: T3KE), Lyxor MSCI Disruptive Technology (WKN: LYX0ZG), Invesco EQQQ Nasdaq-100 UCITS ETF (WKN: 801498), Bit Digital, Riot Platforms, Applied Digital, Iris Energy, Marathon Digital, Bejing Kunlun Tech, Meta, Adobe, Spotify, Palo Alto Network, Nvidia, Oracle, Intel, Paypal, Apple, Dexcom, Fortinet, Microsoft, Equinix und Tesla. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Donna Kozik my book coach takes Mounjaro the diabetes drug that the U.S. FDA will likely approve for weight loss later this year.  Mounjaro is supposedly the most powerful of all the buzzy weight loss drugs you've been hearing about like Ozempic, Wegovy, and Rybelsus that have the ability to both control blood sugar and cause weight loss.  Made by Eli Lilly, studies have shown this diabetes drug can lower body mass at its highest dose by up to 15%. According to the American Diabetes Association, sometimes losing just 5% -7% of your body weight is enough to imporove diabetes control. For someone who weighs 200 poinds this is a weight loss of just 10-15 pounds.   Donna is an open book about taking Mounjaro and is excited to share her A1C dropped nearly 5 points to put her in the diabetes under control range.  Part of her story is also that she hasn't lost any weight yet.  Enjoy the podcast of our live conversation on The Debbie Nigro Show about Donna's experience with Mounjaro. For those of you who would rather read about it the audio transcript is below  BTW: Donna's been helping me get my new book done and out there ‘any minute' lol. She's had extreme patience with me. She's the best! Four out of five people want to write a book . The ones who decide to get it done, like me, need a ‘Donna'. Tell her I sent you at doneforyoupublishing.com     ******************************************************************************************** AUDIO TRANSCRIPT: 0:00:00 And now, back to the Debbie Nigro Show. 0:00:18 I listen the more I learn, and then I share with you guys, and then I ask you to listen some more, because then we learn together. Hey, everybody, I'm Debbie Nigro. Wellness is my topic of the day today. I do a whole show once a week on wellness stuff. And of course, there's a lot of buzz continuing about all these drugs out there for weight loss. You've heard the buzz, right, about Ozempic, Lugovy, Riebelsis, but it seems the most powerful of all these buzzy weight loss drugs is called Mounjaro. It's made by Eli Lilly and it's a diabetes drug that can lower your body mass and it's pretty darn effective. So much so that I got a gal pal I want to introduce to you who loves talking about this because it really helped her a lot. This is Donna Kozik you're about to meet. We're going out west to the other part of the United States. She's a very special person in my life who I've never met. Can you imagine? Book coach helping me. We're about to nail that book together finally after five years, but right now she's alive and well and doing so great because she takes Manjaro and she's going to share the excitement about that. Hey Donna, how are you buddy? Hey Debbie. What's going on over there? 2 0:01:35 Oh, it's a sunny day here in San Diego. Can you believe that? 1 0:01:39 No, I can't. We've had a lot of challenges with weather. How's the weather out there? We're struggling over here on the East Coast. Lots of rain and clouds and smoke from wildfires in Canada. What's going on overall in San Diego? Where I supposedly think there's supposed to be sunshine 364 days a year. 2 0:01:56 Yeah, but you know we're coming off of a really cloudy spring. In fact, one of my clients told me that San Diego was the most cloudy city in the United States outside of one in Alaska during April and May. So go figure. 6 0:02:11 Really? 1 0:02:12 Because that's really a bad sign. I always thought San Diego was the place if I was going to move, I would move there because of how much sunshine they had. 2 0:02:20 Yeah, well, it's sunny now, but we had a cloudy spring just to throw everybody off a little bit. 1 0:02:27 Yeah, you want to keep people away just for a little bit. Donna, I loved communicating with you and thanks so much. I told everybody the latest statistics that four and five people want to write a book, only one out of five ever gets it done. I told them that if they're the one who really wants to get it done, they should call you. They need a Donna. And I thank you for standing by me and helping me forward. And we'll talk about that in another show, but part of my excitement of knowing you is seeing you get well. I didn't know you weren't well, but you seem to be getting weller since I've met you and this manjaro is part of the reason? 2 0:03:02 Yeah, you know, like a lot of people, I've struggled with my weight actually my entire life. I was thinking about our conversation this morning. I went on my first diet when I was five years old when some teachers told my parents that I was overweight and also 12 teenage years, it's just my entire life and I've tried all the programs, Weight Watchers and just all kinds of them and just have never been able to find a solution that not only helps me with weight loss but now helps me with controlling my A1C with diabetes. More importantly, Debbie, what I have found in Manjaro has really helped me physically not crave food. And this is something brand new that no other program has ever helped me with. 1 0:03:55 Really? That's kind of what I'm getting at, that people don't desire to eat because eating for many people like you and me, Donna, is emotional. It's like, you know, you're not hungry, but you love the food, so you just, for whatever reason, you're happy, you're sad, you're celebrating, you're miserable. There's always a reason to eat if you're an emotional eater. And I, too, struggled with my weight since I was a little girl. You know, my mother used to try and make melba toast and, you know, try and get me to lose weight at like eight years old. It's just a psycho existence. It's frustrating, right? So this is exciting. You did say to me that yes, your A1C went down and for people who don't know, that's a way of measuring blood sugar, right? And that's most people have type 2 diabetes. The A1C test measures your average blood sugar level over the past couple of months, the higher your level, the higher your risk of developing diabetes-related problems. And people who have been taking Manjaro, correct me if I'm wrong, it's helping their A1C levels go down to where it's not dangerous. Are you out of danger? 2 0:04:59 Yes, I'm out of danger. On three months of Manjaro, my A1C dropped almost five points and went into what's considered 5 0:05:11 controllable levels. 2 0:05:12 Yeah. Yeah, just a huge relief with that. 1 0:05:17 Wow. But you did say, and this is crazy because I assumed you'd be losing weight as well, that you didn't lose any weight, which I found a little surprising since this is supposed to do that too. Talk to that. 2 0:05:29 Yeah, so it is a little surprising, but there's one thing I want to mention first, and I talked about all those different programs and you mentioned about emotional eating which I totally understand and you know kind of growing up with when things are feeling bad or sad or whatever you go make a sandwich like it was just the answer to everything. But for the first time, Manjaro, what it has helped me with is actually feeling normal and this is something that I have talked to coaches and counselors and nutritionist about for years. It's like, why can't I eat, or it seems like I eat like a normal person, but normal people can have cookies in the house and not eat them, or they can leave a plate with food still on it. And there was a part of me that I just could never understand that and I could never do it until I started this drug, where it fills up my stomach and I feel differently about food. I think differently about food and that to me is the real power of these types of weight loss drugs. 1 0:06:37 Amazing. Oh, it's terrible. The FDA, and you're probably aware of this too, is about to approve this particular drug from Eli Lilly, which they're calling the most powerful of them all in the category that is the same as Ozempic and Wachovian rebelsis because they've really seen the ability for it to both control blood sugar and cause weight loss. They said at the highest dose, and I want to ask you about your dose, that people who have taken this have shown to lower their body mass by up to 15 percent. What dose 2 0:07:15 are you taking? Yes, so you start off at 2.5 and it goes up to 15 and I'm currently on 10. Some doctors, frankly I've been educating my doctor a little bit about it because she can't know everything about everything in some regards and also we're so well educated because of commercials and articles that we can read ourselves that the weight loss generally comes later as you increase your dose. So that's one thing that's giving me a little bit of hope. Also that but some doctors will say, well your A1C is down so let's not increase the dose. But from what I understand the power of the drug is that when it comes to that weight loss is as you grow the dosage because what it does is it works with the hormones in your stomach to make you feel full and it kind of mimics sleep 1 0:08:32 surgery with the idea that the food leaves your stomach at a slower rate and so then 2 0:08:39 that's part of what helps you eat less. that effect can lessen unless you increase the drug to the 15, the dose of 15. 4 0:08:52 Yeah, wow. 2 0:08:53 Have you been on other diabetes medications before Mount Jaro? I'm just curious. 1 0:08:58 Yes, I actually tried Ozempic. I was on Ozempic and it was effective for a little bit of time, but then that effectiveness 2 0:08:54 wonders for her so she encouraged me to ask my doctor about it. Okay, very cool 1 0:09:00 and then you know you're watching, you've heard that if people go off this then they seem to gain weight back or I don't think that once you're on a diabetes drug you can just go off it you have to have a replacement for the drug so you feel like this is your answer and you're going to continue on. There are other drugs obviously. 2 0:09:18 Right. Everybody's like, you know, concerned. Like, well, do you have to be on this drug forever? I'm like, I don't care if I do, if it works. Now, I do take other medications for my diabetes and when my A1C dropped, I was able to eliminate one of them and I believe when I lose weight I'll be able to eliminate others and then we'll see about this one but you know I'm going to worry about today today and think about tomorrow tomorrow. 1 0:09:48 Very interesting because people who do lower their A1C and bring it down like you're doing and you know start losing the weight then their diabetes sometimes just goes away. I mean it's just incredible. So this is a very interesting time in the world. We have a major problem in this country and my own dad, and I've mentioned it on the show before, Don, passed away at the age of 55 from complications of diabetes. So I watched a man suffer that nobody wants to see suffer when it doesn't go right. You know, it was just terrible. And it's just, you know, staying in the lane for the new science, right? And then being able to get the drug. Had you had any problems getting Mount Jara because there was as I understand it a supply chain backlog that was keeping people who needed it for diabetes from getting it because everybody was racing to get it for weight loss. What was your experience with that? 2 0:10:39 Yes, that is true and that there was a or there is a run on these drugs and I'll kind of leave that kind of talk, it's just like well you want to get it to the people who need it primarily and focus on that. I wasn't able to fulfill my prescription from through one store so 1 0:11:26 myself and a couple of friends, we called all the pharmacies in the San Diego 2 0:11:17 This is when I needed the 7.5 and I was able to find a pharmacy that has it and they seem to continue to have it. 1 0:11:25 Oh, that's incredible and yes, I appreciate your story. I was actually reading today how to get Monjaro in 2023, which, you know, it's a brand name for what a drug called, am I saying this right, terzepatide? I don't know if I'm saying it right. Anyway, they said a lot of it you can get online. I was like, what? And yeah, telehealth can prescribe this. I didn't know. I didn't know this at all. Did you? 2 0:11:53 No. You know, people are kind of trying different things. And you know, actually, Debbie, I think it's good that patients and people in general can be more educated now and Actually ask doctors about it and things like that. This is the Wild West When it comes to weight loss drugs and I'm certain we'll find our way eventually But I think it's a good thing that we are we can we can ask about these things. I Do too. I really do I think 1 0:12:19 Diabetes and obesity and just people who struggle with their weight their entire lives is like it just keeps them from living the life they really should be living on this planet. If we were able to help crack this incredible challenging code here, boy, a lot of people would have better lives and better times and experiences and less illness and less mental illness because it's a lot combined in there. It really is. It's about self-esteem and confidence and everything, right? Everything. It's just a meaningful time. 2 0:12:53 We could talk for a few hours plus probably about this. Yep. There's just one thing I just want to encourage people who are listening to this and that is if you are feeling frustrated with your way to, of course, diabetic care to seek out answers and solutions and this could be one of them for you. And I think just as a society, we have been just saying for years calories in, calories out but it doesn't work that way and every individual could be different. And so find the solutions that work for you not only with medicine but also emotional emotional help, nutritional help, physical kind of things, it's all combined. And keep seeking those answers because I believe they're out there for you. 1 0:13:48 Yeah, great point Donna. Last question for you dear. Nobody likes to talk about the downside of things they are hopeful about, but did you have any side effects from Mount Jaro that you didn't see coming or you knew were possible? 2 0:14:01 Yeah, a little bit of digestive issues, but those went away after I was on it for about 1 0:14:08 60 days. All right, awesome. Donna Kozik, tell everybody what the name of your company is in case they need your help because I'm so glad I have you in my life. Anybody who wants to write a book and wants to actually get it done, she's an amazing buddy to have, book writing and publishing coach for her company. It's doneforyoupublishing.com, am I right? 2 0:14:28 we're calling it now? Yes, done for you publishing.com you can pick up your own publishing checklist there. Debbie I'm so excited about publishing your book I can't wait to talk to you about that next time. I can't believe we're not 1 0:14:41 getting it done it's called how to talk to strangers advice from a professional stranger talker and we had a lot of laughs about it hopefully we'll have more Don I love you wish you continued great health and thanks for taking the time on the show today. 2 0:14:52 Love you too, Debbie, anytime. Love you too, Debbie, anytime.

Last Call examines the stratospheric rise of Eli Lilly and how excitement around weight-loss drugs could serve as a double-edged sword.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über neues Hype-Futter bei NovoNordisk, Spekulationen über Grand Theft Auto VI und enttäuschte Hoffnungen bei Upstart. Außerdem geht es um Intesa Sanpaolo, Unicredit, Bper Banca, Deutsche Bank, Commerzbank, BNP Paribas, ING, Banco Santander, NovoNordisk, Eli Lilly, Bayer, LVMH, Bank of New York Mellon, State Street, Moody's, Lyft, Uber, TSMC, Infineon, NXP, Upstart, Take Two, 10x DNA (WKN: DNA10x), ARK Innovation (WKN: A14Y8H), Global BIT Internet Leaders (WKN: A2N812), Dirk Müller Premium Aktien (WKN: A111ZF), Dirk Müller Premium Aktien Offensiv (WKN: A2PX1T), PI Global Value Fund (WKN: A0NE9G), PI Vermögensbildungsfonds (WKN: A1J3AM), Grönemeyer Gesundheitsfonds Nachhaltig (WKN: A2PPHK), Xtracker MSCI World Health Care (WKN: A113FD), Zukunftsfonds (WKN: A2DTM6), Paladin One (WKN: A1W1PH) und Berkshire Hathaway. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über eine neue Kryptowährung bei Paypal, eine Bauchlandung für Biontech, den Abschied vom Master of Coin bei Tesla und einen seltsamen Aktienrückkauf von Palantir. Außerdem geht es um Daimler Truck, GEA Group, Amgen, Horizon, Berkshire Hathaway, Pfizer, Moderna, Siemens Energy, Rheinmetall, General Dynamics, OHB, Beyond Meat, Hims & Hers Health, Chegg, Commerzbank, Deutsche Bank, Deutsch Telekom, E.on, Zalando, Continental, Vonovia, Covestro, Apple, Microsoft, Alphabet, Meta, Amazon, Nvidia, Johnson & Johnson, Wal-Mart, Siemens, SAP, Münchener Rück, Deutsche Börse, DWS ESG Investa (WKN: 847400), DWS Deutschland (WKN: 849096), DWS Aktien Strategie Deutschland (WKN: 976986), UniFonds (WKN: 849100), Fondak (WKN: 847101), Concentra (WKN: 847500), Bristol-Myers Squibb, Abbvie, Eli Lilly und Evotec. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

By one count, a drugmaker founded in 1876 is a more expensive stock than Tesla. (Time Stamp)  Ricky Mulvey and Bill Barker discuss: - Tesla's CFO departure. - Eli Lilly hitting an all-time high, and the drugmaker's optimistic results. - How Burger King is driving sales growth with limited time offers. - Zoom calling its employees back to the office. Companies discussed: TSLA, LLA, NVO, QSR, ZM Host: Ricky Mulvey Guest: Bill Barker Engineer: Rick Engdahl

Carl Quintanilla, Jim Cramer and David Faber began the hour by breaking down Moody's decision to cut its ratings on 10 U.S. banks, which dragged on the broader markets and the financial sector. On the bright side, pharma names rallied after Eli Lilly reported better than expected profit and revenue. Shares of Novo Nordisk also surged after key trial data showed its drug Wegovy cuts risk of heart attack or stroke by 20%. Also in the mix: UPS cut its margin and revenue forecasts following weak e-commerce demand and the company's new labor contract. Squawk on the Street Disclaimer

European bourses are lower given the risk tone post-China trade, banking names lag after an Italian windfall taxStateside, futures are also in the red and feature continued underperformance in the RTYGiven the tone after downbeat Chinese trade the DXY continues to lift with Antipodeans laggingBunds surpassed last week's best after a strong Bobl auction with the complex bid on the tone ahead of US 3yr supply & Fed speakCommodities are broadly pressured given the above factors though spot gold is somewhat cushioned by its haven allureLooking ahead, highlights include US Trade, US IBD/TIPP Economic Optimism. Speakers incl. Fed's Harker & Barkin. Supply from the US. Earnings from Eli Lilly.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Apple and Microsoft have each fallen more than 10% from recent highs, losing a combined $500b in market cap in the process. How should you trade the moves lower, and what do they mean for the broader market? Plus, all eyes on Eli Lilly ahead of its earnings report. What you should expect from the drug maker, and how new trials out of Novo Nordisk could change the game.  Fast Money Disclaimer 

Today, we're speaking with Coach Monique Betty, PCC — a former executive from Coca-Cola and Eli Lilly, who came to coaching some 17 years ago — the early days of the profession. Along the way, she spent five years as a coaching instructor, took part in rewriting the ICF's code of ethics, and today helps high performing career strivers achieve their ambitions faster — and more importantly — more in line with who they truly aspire to be. You can find our more about and connect with coach Monique Betty on LinkedIn, but first, get to know hew here, on the Coach's Corner podcast. Find Coach Monique Betty here: https://www.linkedin.com/in/moniquebetty1/And, find your host, Eric Goeres, right here: https://www.ericgoeres.com/And, ICF South Florida: https://www.icfsouthflorida.org/

**At 6:35 Umberto says “in 2000” instead of the intended “in 2020”Umberto Meduri is a professor of pharmaceutical sciences, and a former professor of medicine at the University of Tennessee Health Science Center, in Memphis Tennessee.Paul Marik is quadruple boarded in Internal Medicine, Critical Care Medicine, Neuro Critical Care, and Nutrition Science. Paul Marik was a tenured professor of Medicine, and chief of the division of pulmonary and critical care medicine at the University of Virginia Medical School.The pattern of blocking effective, safe, generic medications is clearly evident in the story of Umberto Meduri, an excellent physician and researcher who made a remarkable discovery about inflammation of the lung, and a safe and effective treatment with the potential to save hundreds of thousands, possibly millions of lives annually across the globe. The one problem: the drug in question was out of patent. Instead of receiving a Nobel Prize, Dr. Meduri had his career destroyed, and his reputation ruined with pure propaganda. This story, told for the first time here on The DarkHorse Podcast reveals the full depth of the capture of science and medicine, and allows us to see exactly how our response to Covid ended up the exact opposite of good science and medicine.Visit the FLCCC: www.flccc.net*****Our Sponsors:House of Macadamias: Delicious and nutritious macadamia nuts, in all sorts of configurations. Go to https://www.houseofmacadamias.com and use code DARKHORSE for a 20% discount on all orders, plus a free gift with substantive purchase.*****Find Bret Weinstein on Twitter: @BretWeinstein, and on Patreon. Please subscribe to this channel for more long form content like this, and subscribe to the clips channel @DarkHorse Podcast Clips for short clips of all our podcasts. Check out the DHP store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://www.store.darkhorsepodcast.orgTheme Music: Thank you to Martin Molin of Wintergatan for providing us the rights to use their excellent music.*****Timestamps:(00:00) Introductions(03:20) Sponsors(06:00) Origin story(12:15) Inflammation(26:10) Obvious remedies ignored(38:45) What could have happened(42:05) Doctors were targeted(48:35) Coup against medicine(54:20) History of steroid use(01:10:24) Publishing drug trials and peer review(01:18:17) Umberto's RCT and misconduct charge(01:42:00) Eli Lilly's drug for ARDS(01:49:50) Big Pharma callousness(01:53:20) COVID early treatments ignored(02:02:20) Needless death(02:10:15) EUA and mRNA(02:16:25) COVID protocols(02:21:40) Wrap upSupport the show

Acusación histórica para un expresidente de los EE.UU.Un país conmocionado y dividido.Corte de apelaciones deja en vigor las restricciones a la política de asilo.La administración Biden planea expandir el programa de toque de queda.La policía rescata en México a migrantes hacinados.Buscan nuevas posibles víctimas de un agresor sexual.El hijo del presidente colombiano salpica por corrupción muchos nombres.Acción legal contra Novo Nordisk y Eli Lilly.Escucha de lunes a viernes el ‘Noticiero Univision Edición Nocturna' con Maity Interiano y León Krauze.

The 95% of Behavior Marketers Ignore Neale Martin, Sublime Behavior Marketing   – The Sharkpreneur podcast with Seth Greene Episode 952 Neale Martin Neale Martin is co-founder and CEO of Sublime Behavior Marketing, a behavioral marketing consulting firm dedicated to helping clients change customer and organizational behavior. His best-selling book Habit: The 95% of Behavior Marketers Ignore, updates marketing principles and practices based on pioneering brain research that reveals most consumer behavior is the result of unconscious habits and not deliberative choices.  Neale works with clients to understand and influence the conscious and unconscious drivers of customer behavior. These insights influence product design, development, advertising campaigns, and product launches, as well as decisions not to launch or to avoid certain markets. Sublime Behavior uses an innovative and proprietary research methodology that decomposes customer behavior into its Intuitive and Executive mind components. Recently, clients engage Neale to apply these behavioral methodologies to organizational change. Sublime works with companies across diverse industry sectors including telecom, consumer electronics, consumer packaged goods, energy, technology, and pharma. His client list includes Samsung, P&G, Coca-Cola, Verizon Wireless, Campbell's Soup, Eli Lilly, Merck, Godrej, Axiata, J. Walter Thompson, and Shell Oil.     Listen to this informative Sharkpreneur episode with Neale Martin about the 95% of behavior marketers ignore. Here are some of the beneficial topics covered on this week's show: - How Neale's book combines psychology, neuroscience, and marketing theories to explore the power of habits in consumer behavior. - Why our unconscious brain drives our habits and how our conscious brain rationalizes these actions. making it difficult to understand what truly drives consumers. - How consumers being driven by their subconscious makes it challenging to understand the true drivers of consumer behavior. - Why making consumers consciously think about their actions disrupts existing habits and helps them form new ones. - How simplifying the decision-making process can drive market adoption and attract customers.   Connect with Neale: Guest Contact Info Links Mentioned: sublimebehavior.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Barely a day goes by without more headlines around new weight-loss drugs, from the issue of global shortages, to investigations into suicide risk, and debate over just how long people will need to be on them. But in this episode of Inside Health we're going to look at something slightly different - and perhaps unexpected. James Gallagher meets lifelong dieter Cheri who has lost just over three stone on semaglutide but she's also noticed other effects from her weekly injection; a calmer mind and a complete lack of desire for her much-loved vapes. She wants to know what's going on – so we seek out some scientists to help us get to the bottom of it. From the evidence gathered so far, are there hints that these drugs could offer potential to treat serious addiction? And have you ever heard of “bed rotting”? It doesn't sound particularly enticing - but James gives it a go in the name of science and we explain all in the programme with the help of two experts. What health questions do you want us to answer? Email the team at insidehealth@bbc.co.uk Declared interests: Professor Giles Yeo: "I have a PhD student part-funded by Novo Nordisk. I consult for Novo Nordisk and Eli Lilly." Dr Tony Goldstone: "I have previously been a member of Data Safety Monitoring Board for clinical trials of Liraglutide for obesity by Novo Nordisk, and have received an honorarium as a conference speaker from Novo Nordisk." Presenter: James Gallagher Producer: Gerry Holt Editor: Erika Wright Production Coordinator: Jonathan Harris Studio Producer: Duncan Hannant (Photo: Cheri Ferguson with her Ozempic pen. Credit Cheri Ferguson)

In this episode of Medsider Radio, we sat down with Kate Rumrill, CEO of Ablative Solutions, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.Before we jump into the conversation, I wanted to mention a few things:If you're into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You'll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you're interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Kate if you prefer reading.

Dementia affects 55 million people worldwide, and its most common form, Alzheimer's, accounts for about 70 percent of all cases.At the Alzheimer's Association International Conference, the largest congress advocating dementia science, held in Amsterdam this month, a pharmaceutical company disclosed details of its trials of a new drug: donanemab.The American company, Eli Lilly, expects the United States Food and Drug Administration (FDA) to decide by the end of 2023 whether to approve what it is calling a "breakthrough" drug.But is this medication the best way forward? Or does it just supply cash flow for the pharmaceutical industry?Leading dementia scientists Edo Richard and Craig Ritchie talk to Al Jazeera.Subscribe to our channel http://bit.ly/AJSubscribeFollow us on Twitter https://twitter.com/AJEnglishFind us on Facebook https://www.facebook.com/aljazeeraCheck our website: http://www.aljazeera.com/Check out our Instagram page: https://www.instagram.com/aljazeeraenglish/@AljazeeraEnglish#Aljazeeraenglish#News

Synopsis: Greg Flesher is the President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases with significant unmet medical needs. Greg discusses beginning his career at Eli Lilly in the mid 1990s and how he approaches being a CEO differently the second time around. He talks about the rare mitochondrial disease landscape and the opportunities and challenges within it. He also dives into patient access for rare diseases and the difficulties around accessing the right patients for late-stage pivotal trials. Finally, he shares how the current environment impacts how he approaches execution against clinical programs and his advice to other leaders navigating the current times. Biography: Greg is the President and Chief Executive Officer of Reneo Pharmaceuticals and serves as a member of the company's Board of Directors. Greg brings to Reneo more than 25 years of biopharmaceutical industry experience in executive management, corporate and business development, operations, sales and marketing, and clinical development. He has been closely involved with several novel development programs resulting in multiple product approvals and successful commercial launches in the U.S. and Europe. Prior to joining Reneo, Greg was Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics (Nasdaq: NVUS), a clinical-stage pharmaceutical company he took public in 2017 and led through the transformational acquisition of Anelixis Therapeutics in 2020. Prior to Novus, Greg was Chief Business Officer of publicly traded Avanir Pharmaceuticals (AVNR), a commercial-stage pharmaceutical company, where he led corporate and business development as well as corporate operations through the $3.5 billion acquisition of the company by Otsuka Pharmaceuticals in 2015. From 1995 to 2006, Greg held multiple leadership roles at Intermune (acquired by Roche), Amgen, and Eli Lilly and Company. Greg received his B.S. in biology from Purdue University and studied biochemistry and molecular biology at Indiana University School of Medicine.

The drug company Eli Lilly has developed an experimental drug to treat dementia. It has found that the drug could have a dramatic effect in slowing down the disease. However, dementia is not just one thing, Alzheimer's disease is the most common form, but Lewy Body Dementia is the second most common. Kevin Quaid is an activist and author who is living with Lewy Body Dementia and he joined Sean to discuss…

Don`t Call It A Lockdown - From Chemical to Criminal CastrationWebsite: http://www.battle4freedom.comNetwork: https://www.mojo50.comStreaming: https://www.rumble.com/c/Battle4FreedomStreaming LIVE on RUMBLE @ https://rumble.com/v30pht0-dont-call-it-a-lockdown-from-chemical-to-criminal-castration.htmlhttps://www.dailymail.co.uk/health/article-12308531/FDA-approves-shot-cold-like-winter-virus-kills-hundreds-babies-year.htmlFDA approves shot for cold-like winter virus that kills hundreds of babies each year-The FDA has approved a new shot to treat RSV in children and toddlers-The medication is expected to be available by the upcoming fall RSV seasonhttps://www.dailymail.co.uk/health/article-12307257/Alzheimers-drug-Eli-Lilly-slows-early-Alzheimers-60-hailed-turning-point-fight-against-disease.html'Turning point' in fight against Alzheimer's: Scientists hail drug made by Eli Lilly that slows early stage of disease by up to 60% as 'defining moment' in dementia research-It is the second treatment after lecanemab to offer hope to patients with disease-Could be available to millions of Americans in just 18 months - in breakthroughhttps://www.dailymail.co.uk/news/article-12309431/America-smoked-Biggest-smoke-plume-Canadian-wildfires-blanket-23-states-today-Code-Orange-warnings-issued-vulnerable-residents-stay-indoors.htmlAmerica is smoked out AGAIN: Biggest smoke plume yet from Canadian wildfires to blanket 23 states today as Code Orange warnings issued for vulnerable residents to stay indoors-Nearly half of US states are predicted to be impacted Tuesday by smoke moving down from Canada -It is the largest smoke plume recorded so far this year -The smoke is expected to disperse by Wednesday when it will be pushed off the East Coasthttps://www.dailymail.co.uk/news/article-12309415/San-Francisco-Walgreens-resorts-CHAINING-refrigerator-section-overnight-stop-shoplifters-swiping-pizza-ice-cream-20-times-day.htmlSan Francisco Walgreens NOW resorts to CHAINING their freezers to stop shoplifters in crime-riddled city swiping pizza and ice cream 20 times a day - as another branch completely boards up its windows-A San Francisco pharmacy has taken extreme measures to protect their goods padlocking freezers shut, tying metal chains to ensure the doors remain closed -Video captured by a potential shopper at a local Walgreens shows aisle after aisle of products including lower-value items stuck behind Perspex and glass -Rampant theft is plaguing many of the city's pharmacies with shop workers reporting instances of thieves coming into the store as many as 20 times a dayhttps://www.dailymail.co.uk/news/article-12308207/LAPD-union-boss-tells-cops-LEAVE-city-understands-worth-failed-salary-negotiations-1-000-officers-left-2019.htmlLAPD union boss tells cops to LEAVE the city and 'go somewhere that understands your worth' after failed salary negotiations: More than 1,000 officers have left since 2019-LAPPL boss Jerretta Sandoz told officers to leave the LAPD for other cities-Since 2019 the number of LAPD officers dropped by 10 percent to around 9,000https://youtu.be/lNSg5TlwB6kordan B Peterson interview: Speaking Softly and Carrying a Big Stick|Mike Pence|EP 368

US pharmaceutical giant Eli Lilly will unveil the full results of its trials of the drug 'donanemab' - which is the second shown to slow progression of dementia. The results of the donanemab trial will be revealed at the Alzheimer's Association International Conference in Amsterdam, and the drug could be licenced as safe in the UK in as little as a year to 18 months. The NHS would then have to weigh up the cost effectiveness when it comes to who it can give the drug to. Today's Mishal Husain speaks to Hilary Evans, Chief Executive of Alzheimer's Research UK and Co-Chair of UK Government Dementia Mission, and Professor Sir John Hardy, Professor of Neurodegenerative Disease at UCL - who advised the pharmaceutical company Eli Lilly during the development of donanemab. Photo credit: Denis Balibouse, Reuters